Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Stemchymal in Acute Liver Failure
NCT03629015Phase 1Withdrawn
- Sponsor
- Steminent Biotherapeutics
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Stemchymal in acute liver failure (ALF) and acute-on-chronic liver failure (ACLF), sponsored by Steminent Biotherapeutics. Primary endpoint: The incidence of adverse events (AEs) and suspected unexpected serious adverse reaction (SUSAR) at 12 months. Planned start Oct 2018; status: withdrawn.
02
Drugs
Stemchymal
03
Conditions
acute liver failure (ALF)acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03629015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629015.